Arca
Skip to content
Tools
Tools

MGAM: Maltase-glucoamylase

Alpha-(1,4) exo-glucosidase involved in breakdown of dietary starch oligosaccharides in small intestine.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on MGAM, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Other 1

Approved2

  • Acarbose
  • Miglitol

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        AcarboseApprovedBayerOligosaccharideInhibitorMaltase-glucoamylase inhibitor5
        MiglitolApprovedPfizerSmall moleculeInhibitorMaltase-glucoamylase inhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.
        A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseaseAcarbosePhase 2Active, not recruitingBeijing University of Chinese MedicineOct 30, 2026
        Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentAcarbosePhase 4RecruitingFudan UniversityJul 17, 2026
        Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 DiabetesAcarbose—Not yet recruitingShanghai General Hospital, Shanghai Jiao Tong University School of MedicineFeb 17, 2026
        A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 DiabetesAcarboseNot applicableNot yet recruitingHaisco Pharmaceutical Group Co., Ltd.Aug 14, 2025
        A Trial With EMP16 in Preparation for Late Phase StudiesAcarbosePhase 2Not yet recruitingEmpros Pharma ABMay 28, 2025

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Type 2 diabetes mellitus
        0.60
        Systemic inflammatory response syndrome
        0.34
        Cardiovascular disorder
        0.32
        Type 1 diabetes mellitus
        0.26
        Endothelial dysfunction
        0.26
        Tympanic membrane perforation
        0.20
        Tympanic membrane disorder
        0.20
        Myotonic syndrome
        0.12

        Genes and related targets

        Complexes and families that share a gene with this target
        Genes
        MGAM

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2074, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt O43451, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.